Activation of the Drosophila EGF-receptor (DER) is spatially and temporally controlled by the release of its various ligands. DER and its ligand Spitz mediate the formation of specific somatic muscle precursors. We show that a second DER ligand, Vein, complements the activity of Spitz in the development of various somatic muscle precursors. In vn mutant embryos, the DER-dependent muscle precursors do not form in some of the segments. This phenotype is significantly enhanced in embryos carrying only one copy of wild type spitz. Our analysis suggests that Vein activation of DER differs qualitatively from that of Spitz in that it does not lead to the expression of the inhibitory protein Argos, possibly leading to a continuous activation of the DER signaling pathway.
Introduction
Locomotion of the Drosophila larva is achieved through coordinated contractions of an array of somatic muscles attached to the larval epidermis (Bate, 1990 (Bate, , 1993 . The identity of each of the~30 types of somatic muscle fibers is determined during early embryonic stages from a set of muscle founder cells (Rushton et al., 1995) . Each founder cell defines a specific muscle fiber identity, characterized by a unique size, position, and orientation for reviews see (Bate, 1993; Abmayr et al., 1995) . Muscle differentiation is achieved when myoblasts expressing high Twist levels fuse to a given founder myoblast and follow its specific pattern of gene expression (Baylies and Bate, 1996) . Different founder myoblasts express a specific repertoire of genes characteristic of their distinct fate, e.g. S59 (Dohrmann et al., 1990) , even-skipped (Frasch et al., 1987) , vestigial (Williams et al., 1991) , apterous (Bourgouin et al., 1992) , nautilus (Michelson et al., 1990) , connectin (Nose et al., 1992) , and krüppel (Gaul et al., 1987) .
The founder myoblasts are the product of distinct lineages that are initiated by the segregation of a special class of muscle progenitors. Each progenitor divides asymmetrically to give rise to two distinct founder myoblasts, or a founder and the precursor of an adult muscle (Carmena et al., 1995; Baylies et al., 1998) . The activity of inscutable and numb genes in the progenitor asymmetric cell division has been recently described Carmena et al., 1998) . Muscle progenitors are selected in a process reminiscent of neuroblast segregation which similarly requires the neurogenic genes (Hartenstein et al., 1992) . A single progenitor is selected from a cluster of cells expressing lethal of scute (l'scute) to retain high levels of L'scute and in addition it expresses a particular subset of identity genes (mentioned above). Specification of the progenitor cell is influenced by an extrinsic mechanism involving intercellular signaling molecules such as those encoded by the wingless (wg) and decapentaplegic (dpp) genes (Staehling-Hampton et al., 1994; Baylies et al., 1995; Frasch, 1995; Lawrence et al., 1995; Park et al., 1996; Ranganayakulu et al., 1996) .
Another mechanism essential for the specification of a subset of muscle progenitors is the Drosophila EGF-receptor pathway (Buff et al., 1998) . In the absence of the recep-tor (DER/Egfr), or its ligand, Spitz, specific muscle founder cells, including the precursor of DA1 (dorsal acute muscle no. 1), VA2 (ventral acute muscle no. 2) and LL1 (lateral longitudinal muscle no. 1), are missing, leading to a loss of these specific muscle fibers. The loss of DA1 muscle founder myoblast in DER or spitz mutant embryos results from a defected determination of its specific muscle progenitor P15. In addition, it was suggested that the development of individual muscles is differentially sensitive to variations in the level of signaling by DER (Buff et al., 1998) . DER is a receptor tyrosine kinase, essential for the determination of a wide array of cell fates during embryonic development (Ray and Schupbach, 1996; Perrimon and Perkins, 1997; Schweitzer and Shilo, 1997) . The regulation of the activity of the DER-signaling cascade is thought to be accomplished by localized release of its ligands, since DER is widely expressed in all germ layers throughout embryonic development. Among DER ligands, Spitz, a TGFa homologue, is a major ligand active in a number of tissues (Rutledge et al., 1992) . Spitz is produced as a membrane-bound protein and is processed to produce an extracellular, active form (Schweitzer et al., 1995b) . A function for Rhomboid in the regulation of Spitz processing has been suggested (Golembo et al., 1996a) .
Vein, an additional ligand for DER (Schnepp et al., 1996; Yarnitzky et al., 1997) , is a secreted growth factor containing Ig-like and EGF-like domains at its C-terminal. The embryonic expression of vein mRNA is dynamic and marks a number of tissues where the Spitz ligand was reported to be the active ligand. These tissues include the ventral ectoderm (Schnepp et al., 1996) , tracheal pits (Schnepp et al., 1996) , and somatic muscle precursors (Buff et al., 1998 ; and see also the present work). Despite its restricted embryonic expression pattern, no obvious phenotype in these tissues has been reported in vein mutant embryos. During late stages of embryonic development, Vein is expressed in all the somatic muscles, and is required, independently of Spitz, for the muscle-dependent differentiation of tendon cells (Yarnitzky et al., 1997) .
Genetic evidence described in Schnepp et al. (1996) suggests a functional link between both DER ligands. For example, reducing Vein levels in a spitz null genotype worsened the phenotype to produce a collapsed embryo with an extruded head skeleton. In addition, ventral denticles and head skeleton defects in spitz;vein double mutants were more severe than the predicted additive phenotype of the single mutants. This led to the hypothesis that both ligands function in a synergistic manner in certain tissues. Recently, both Vein and Spitz were found to be required for specification of neuroblasts along the dorsal-ventral axis during early embryonic development (Skeath, 1998) .
In the present work, we show that Vein is required to complement Spitz in the development of a subset of muscle precursors whose differentiation depends on DER activity. In vein mutant embryos these muscle precursors do not form in some of the segments. This phenotype is not fully penetrant, but is significantly enhanced in embryos carrying only one copy of wild type spitz, or in embryos in which the activity of DER is reduced by expressing a dominant-negative form of the receptor. Ectopic expression of Vein in the mesoderm is sufficient to induce supernumerary DERdependent muscle founders in wild type, spitz, or rhomboid mutant embryos. Unlike Spitz, Vein activation of DER does not lead to the expression of the inhibitory protein, Argos. These results led us to suggest a model in which Vein is required to complement Spitz activity in the formation of specific muscle precursors by inducing a continuous activation of the DER signaling pathway, following the activation of this receptor by Spitz.
Results

Vein contributes to the specification of the DERdependent muscle precursors
vein mRNA expression is detected in the ventral ectoderm, somatic mesoderm, tracheal pits and chordotonal organs (Schnepp et al., 1996) . During, and following germ band retraction, vein mRNA expression is observed in a reiterated segmental pattern in a number of muscle precursor cells (Fig. 1A,B ). Double labeling with anti-Vein and anti-Krüppel antibodies reveals that the Krüppel-positive cells also express Vein (an overlap between Krüppel and Vein staining in various muscle precursors is demonstrated in Fig. 1C-E) . Buff et al. (1998) , showed that development of the Krüppel-expressing muscle founders DA1, LL1 and VA2, depends on DER activity. In the absence of Spitz, or in embryos expressing dominant negative DER (DNDER), these muscle founders are missing from all the segments. At stages 12-13 of embryonic development, the DA1 muscle precursor is identified at the dorsal region of the mesoderm by the common expression of Eve and Krüppel in a cluster of several nuclei, representing myoblasts fused to the DA1 founder cell. The precursors of muscles LL1 and VA2 express Krüppel, and can be identified by their relative locations in an embryo at stages 12-13. In vein (vn) mutant embryos at stages 12-13 of embryonic development, the DA1 muscle precursor is missing in one (or occasionally two) segments of mutant embryos (figurehere>Fig. 2B,D). The penetrance of this phenotype is~50% (out of 100 embryos scored). The Krüppel-positive muscle precursors LL1 and VA2 are also missing in vein mutant embryos in a similar frequency as observed for DA1 (Fig. 2F) . No alterations in the severity of the phenotype were noticed in various vn heteroallelic combinations, including vn
. Thus, we concluded that the loss of the various muscle precursor cells observed in vein mutant embryos is in line with the expression of Vein in these cells. In contrast to the phenotype observed in spitz mutant embryos, in which all the DA1, LL1 and VA2 mus-cle precursors are missing (Buff et al., 1998) , the vn mutant phenotype is mild, raising the question of the actual contribution of Vein to that process.
While the occasional loss of specific muscles is detected in vn mutant embryos at earlier developmental stages (e.g. stage 12), during late stages of embryonic development (e.g. stage 15-16), a significant number of the somatic muscle fibers exhibit multiple, mis-guided membrane extensions at their leading edges (Fig. 2G ). This phenotype is the consequence of a defective differentiation of the tendon cells and is not restricted to the specific muscles (e.g. DA1, VA2 and LL1) mentioned above (Yarnitzky et al., 1997) .
The requirement for Vein is enhanced when activation of DER is reduced
The relatively moderate contribution of Vein to the development of the DER-dependent muscle precursor cells raises the possibility that Vein complements or provides a backup mechanism for the activity of Spitz in these cells. In that case it is expected that reducing the activity of DER signaling pathway in the muscle precursor cells during their formation, may enhance the effect of loss of Vein. To test this possibility we followed the formation of the DA1 muscle precursor in embryos in which the activity of DER was reduced by expressing a dominant-negative form of DER (DNDER) in the mesoderm. This was achieved by inducing the expression of UAS-DNDER using the mesoderm-specific 24B-gal4 line. In such embryos, grown at 22°C, the formation of the DA1 muscle precursor (detected by Eve expression), is either normal or affected in not more than one segment (Fig. 3C) . In embryos carrying both a vein mutation (vn P1749 ) and a UAS-DNDER construct induced by 24B-gal4 (at 22°C), the loss of DA1 muscle precursor is enhanced and observed in three to six segments (Fig. 3D) . In contrast to the 50% penetrance observed in the vein mutants, this phenotype is fully penetrant.
To test more directly the model that Vein complements the activity of Spitz in the development of the DA1 muscle precursor, we examined the formation of DA1 muscle precursor in vn mutant embryos carrying only one copy of wild type spitz. While the DA1 muscle precursor is formed in all the segments of embryos heterozygous for the spitz mutation, the vn mutant embryos carrying only one copy of wild type spitz, show significant enhancement in the penetrance (100% compare to 50%) of the phenotype (Fig. 3F ). In addition, the number of affected segments was elevated (three instead of one), as demonstrated in Fig. 3 . Both Fig. 1 . vein is expressed in a subset of somatic muscle precursors. vein mRNA is detected in a subset of somatic muscle precursors during and following embryonic germ band retraction (A,B). Double labeling with anti-Vein (C, red) and anti-Krüppel (D, green) antibodies, indicates that both proteins are colocalized in an embryo at stage 12-13. Panel E represents the merged Vein/Krüppel image. The identity of the various muscles is indicated by arrowheads in C-E. experiments support the model in which Vein activity complements or provides a backup mechanism for the critical contribution of Spitz to the formation of DA1 muscle precursor.
Vein is sufficient to induce the formation of the DERdependent muscle founders
Vein appears to be a relatively weak EGF-receptor ligand compared to Spitz (Schnepp et al., 1998) . Ectopic expression of the active secreted Spitz ligand in the mesoderm results in supernumerary muscle founder cells (Buff et al., 1998; and our unpublished results) . To test the potential of Vein to induce the formation of supernumerary muscle founder cells, we overexpressed Vein in the mesoderm. Such overexpression using the twist-gal4 inducer line, results in the formation of supernumerary Even-skipped positive clusters in the dorsal domain of the embryo (Fig.  4B) , presumably representing overproduction of DA1 muscle founder cells. Additional clusters of supernumerary G) . At the dorsal aspects of such embryo DA1 is missing in 2 segments (arrows in H), while DO1 is also missing in one segment, presumably due to abnormal guidance.
Krüppel positive cells (probably LL1 and VA2 muscle founders) were observed (Fig. 4D) . This confirms that Vein is capable of inducing the formation of DER-dependent muscle founders. A similar result was obtained using the ectoderm-specific gal4 line, krüppel-gal4, although the number of ectopic cells formed was lower (not shown). In addition, we observed that ectopic Eve-positive clusters are formed not only in wild type embryos but also in spitz mutant embryos, or in rhomboid mutant embryos, when ectopic Vein is induced by the 69B-gal4 inducer line (Fig. 4F,G) .
Thus, although Vein appears to be a weak activator of the EGF-receptor pathway compared to Spitz, it is capable, like Spitz, of inducing over production of DER-dependent muscle founder cells, even in the absence of functional Spitz. These experiments also confirm the ability of Vein to act non-autonomously on neighboring cells. Schnepp et al. (1998) showed that the addition of Vein to S2 cultured cells leads to a relative lower levels of activated MAPK, compared to Spitz. We demonstrate that in vivo, overexpression of Vein leads to lower levels of activated MAPK as well. An equal number of embryos carrying either UAS-ssp (the secreted active form of Spitz; Schweitzer et al., 1995b) or UAS-vein, together with the heat-shock gal4 inducer (hs-gal4), were treated with heat shock and analyzed by Western for the levels of activated MAPK. The anti di-phospho MAPK antibody (anti dp-ERK; Gabay et al., 1997) was utilized in the Western analysis. A representative Western blot (of three independent repetitions) together with the calculated intensity ratio of the MAPK Fig. 3 . vein mutant phenotype (B) is enhanced in embryos in which the activity of DER is reduced. The formation of DA1 muscle precursor (detected with anti Even-skipped antibody) is slightly affected (about one segment is affected), in an embryo expressing a dominant-negative form of DER (UAS-DNDER), in combination with the mesoderm-specific 24B-gal4 at 22°C (C). This phenotype is significantly enhanced (three to six segments are affected) in such embryos (as in C), that are in addition, homozygous mutant for vein (vn dddL6 
Vein-mediated activation of the DER pathway does not lead to the induction of Argos
/Df(3L)XAS96 in D). A similar phenotypic enhancement is observed in vein mutant embryos (vn
P1749
) heterozygous for a spitz (spi OE92 ) mutation (F), while in heterozygous spitz mutant embryos the DA1 muscle precursors are formed in all segments (E). Arrows in B-D,F show the segments in which DA1 is missing. In each experiment at least 100 embryos were scored. Panels B,D,F show a representative phenotype of a given experiment. reactive band, normalized against the control band, is presented in Fig. 5 . The level of dp-ERK induced in embryos overexpressing Vein is lower relative to embryos expressing sSpitz. Similar results were obtained when comparing additional independent transgenic lines carrying the UAS-vein or UAS-sspitz constructs.
This observation, together with the results described by Schnepp et al. (1998) , supports the idea that Vein is a weak activator of the DER-mediated signaling pathway. Lower levels of activated MAPK may result in a distinct profile of gene expression induced by Vein. Spitz activation of the DER-pathway leads to positive transcriptional regulation of argos, an inhibitor of the DER pathway (Schweitzer et al., 1995a) . Argos secretion from cells in which the DER signaling pathway has been activated is essential to prevent Spitz from affecting neighboring cells (Golembo et al., 1996b; Freeman, 1997) . We wished to test the ability of Vein to induce transcription of argos, when overexpressed in the mesoderm. Ectopic expression of sSpitz by the twistgal4 inducer leads to the ectopic expression of argos mRNA in the entire mesoderm (Fig. 6E) . Unlike Spitz, the ectopic Note that the effect of ectopic Vein is detected not only in a wild type background but also in spitz (F) or rhomboid (G) mutant embryos. Although 69B-gal4 and twist-gal4 induce expression in distinct tissues (ectoderm or mesoderm respectively), no significant difference in the resulting phenotype of ectopic Vein was noted. Representative Western blot analysis (of three independent repetitions), using anti di-phospho-ERK antibody, as detected in wild type (hsgal4/ + ) embryos, embryos expressing ectopic Vein (hs-gal4;UAS-vein), and embryos expressing ectopic Spitz (hs-gal4;UAS-sspitz) is shown. Each lane represents protein extract made from 15 embryos, which were heatshocked for 20 min, incubated for additional 3 h and subjected to Western analysis. The intensity of the activated MAPK is presented in arbitrary units (see materials and methods). Note that the level of activated MAPK in embryos expressing sSpitz is significantly higher compared to embryos expressing Vein. expression of Vein, induced by the same twist-gal4 inducer, does not lead to overexpression of argos mRNA in the mesoderm (Fig. 6D) . The transgenic line carrying the UAS-vein construct (used in this experiment) represents the strongest insertion line that we have obtained. Embryos which are the progeny of this line, and in addition carry the twist-gal4 inducer (used above), show ectopic expression of orthodenticle (otd) in the ventral ectoderm (demonstrated in Fig. 6B ). The mRNA expression of otd is observed in a row of 2-4 cells wide along the midline at stage 10 of embryonic development (Finkelstein et al., 1990; Kim and Crews, 1993) . This expression is highly dependent on the activation of the DER-pathway in this region (Gabay et al., 1996) . The level of ectopic otd in the UAS-vein flies is indistinguishable of that observed when sSpitz is induced by the twist-gal4 line (Golembo et al., 1996a) . We concluded that Vein activation of the DER pathway differs from that of Spitz with respect to the induction of Argos.
Assuming that the ectopic experiments reflect the in vivo situation in the muscle founder cells, it appears that activation of DER by Vein in these cells may result in prolonged DER activation, since it is not inhibited by Argos. However, since Argos protein may be present due to previous Spitzdependent activation, a prolonged activity of Vein is possible only in case the latter is refractive to Argos.
Discussion
The Drosophila EGF receptor, DER, mediates an array of differentiation events during embryonic, larval and adult development (Ray and Schupbach, 1996; Perrimon and Perkins, 1997; Schweitzer and Shilo, 1997 ). An interplay between the different DER ligands may result in alterations at the level of receptor activation, or duration of the receptor-mediated signaling within the cell, contributing to different developmental consequences. In the present paper we show that coordinated activities of two DER ligands, Spitz and Vein, are essential for the correct development of a subset of embryonic somatic muscles.
While both Spitz and Vein activate the DER-signaling pathway, their potential to activate this pathway differs significantly. The levels of activated MAPK induced by the addition of secreted Spitz to DER-transfected S2 tissue cultured cells, are significantly higher compared to those induced by Vein (Schnepp et al., 1998) . This is consistent Fig. 6 . Ectopic Vein does not lead to ectopic expression of argos. Like Spitz, ectopic expression of Vein induced by twist-gal4 leads to the ectopic expression of otd in the ventral ectoderm (B). Compare otd expression in the embryo in panel B, to otd expression in a wild type embryo (A). In contrast to its effect on the expression of otd, no effect on argos mRNA expression is detected in embryos expressing ectopic Vein (D), utilizing the same gal4/UAS constructs, compare D to wild type argos expression in C. Unlike Vein, ectopic expression of sSpitz (using the same twist-gal4 inducer) leads to high levels of ectopic argos mRNA (E).
with our in vivo analysis of the levels of activated MAPK induced by either secreted Spitz or Vein. The lower activation of DER by Vein may lead to qualitatively different consequences in terms of gene expression. For example we have shown that unlike Spitz, Vein overexpression does not lead to Argos expression. A prolonged expression of Vein in the muscle founders, thus, may lead to a continuous activation of the EGF-receptor pathway in these cells.
Since Vein is a secreted protein, while Spitz is produced as a membrane-bound, non-active DER ligand, distinct mechanisms control their mode of DER activation. Regulation of Vein activity appears to be at the transcriptional level, since its ectopic expression in various tissues (e.g. ectoderm or mesoderm) leads to measurable biological consequences (Schnepp et al., 1998; and our results) . Spitz activity is controlled by the expression of Rhomboid or Star, presumably by its processing into an active secreted form (Schweitzer et al., 1995b) .
Different modes of Vein activity during embryonic development
Although Vein is a less potent activator of DER, it functions as a single ligand in certain tissues, such as in tendon cell differentiation (Yarnitzky et al., 1997) . In this tissue, the limited activation of DER by Vein may be compensated by concentrating it at the site of activity, i.e. at the muscletendon junctional site. The accumulation of Vein at this site may be also essential to restrict the number of affected cells.
Spitz functions in a wide array of embryonic tissues where Vein mRNA is also detected, e.g. the somatic mesoderm, ventral mesectodermal cells, tracheal pits, and chordotonal organs. The biological contribution of Vein in tissues where Spitz appears to be the major ligand (according to the resulting mutant phenotype), could be explained by two alternative mechanisms: Vein could act synergistically with Spitz, or, Vein may act sequentially to Spitz to provide a low, but continuous level of DER activation which is required to backup, or complement Spitz activity. Simultaneous expression of Vein together with sSpitz in embryos, using heat-shock-gal4, did not lead to higher levels of activated MAPK (our unpublished results). Therefore we do not favor the model of synergistic activation of DER by both ligands. To this end, our results support the idea that the role of Vein in tissues where Spitz is the major ligand is to complement Spitz activity. This explains the extremely weak vein phenotype observed in these tissues, in comparison to a significant and measurable phenotype obtained in tissues where Vein functions as a single ligand. It is also consistent with the genetic interaction between vein and spitz, described by Schnepp et al. (1996) .
vein mRNA is also observed in domains in which Spitz or Rhomboid contribution has not yet been described, e.g. the amnioserosa, the dorsal most row of ectodermal cells during germ band retraction and head structures. No obvious phenotype is observed in these tissues in vein mutant embryos and the role of Vein in these tissues is yet to be elucidated.
Vein functions sequentially to Spitz
Vein appears to act sequentially to Spitz since vein mRNA in the somatic mesodermal cells follows Rhomboid expression in the progenitors (Buff et al., 1998) . Rhomboid expression appears to represent the local activation of Spitz (Schweitzer et al., 1995b) . The delayed expression of vein mRNA, is consistent with the suggestive function of Vein as a ligand that complements Spitz activity. It is possible that Spitz activation of DER positively regulates the transcription of vein in the founder cells. In line with this possibility is our observation that overexpression of Spitz leads to the expression of Vein (Golembo et al., unpublished) .
The nature of the inter-relationship between Vein and Argos is yet to be elucidated. Since activation of DER by Spitz leads to Argos expression (Golembo et al., 1996b) , it may inhibit Vein activity. Vein activity in the muscle founders suggests that these cells are either refractive to Argos or that Argos does not inhibit Vein activity.
In summary, an interplay between the temporal expression and differential activities of two EGF-receptor ligands described in this work, may be essential for a robust receptor activation required to accomplish specific differentiation programs.
Materials and methods
Fly stocks
The following gal4 inducers were used: 69B-gal4, twistgal4, 24B-gal4 (A. Brand, Cambridge, UK), krüppel-gal4 (M. Leptin, Köln, Germany), hs-gal4 (K25-2Xsev hsp70-GAL4, obtained from E. Hafen, Zürich, Switzerland). In addition the following strains were used: y w (wild-type strain); Df (3L) (Yarnitzky et al., 1997) . The UAS-vein 110 insertion induces a high expression level and UAS-vein 98 represents a weaker line. Mutant embryos were identified using 'blue balancers' and anti-b-galactosidase staining.
Immunochemical reagents
Vein was visualized either by in situ hybridization with a digoxigenin-labeled 3.4 kb vein cDNA fragment, or by antibody against GST-Vein fusion protein, raised in rats. Argos expression was monitored by in situ hybridization using argos RNA as probe (M. Freeman, MRC, Cambridge). An otd clone was obtained from R. Finklestein (University of Pennsylvania, PA). Anti Krüppel antibody was obtained from C. Rushlow (NYU, New York, NY) and anti Evenskipped antibody was obtained from M. Frasch (Mount Sinai Hospital, New York, NY) . Anti-myosin heavy chain (MHC) antibody was obtained from P. Fisher (Stony Brook, NY). The level of activated MAPK was monitored by anti diphospho-ERK (Sigma). Anti-b-galactosidase antibodies were purchased from Cappel (USA).
Secondary antibodies included HRP, Fluorescein, Rhodamin or Cy3-conjugated Goat or Donkey anti Rabbit or anti Rat IgG (Jackson, USA), and anti-dig-AP antibody (Boehringer Mannheim, Germany).
Whole mount embryonic staining
Staining was performed essentially as described (Ashburner, 1989) . In brief, embryos were collected and incubated as indicated, dechorionated and fixed in a mixture of 3% paraformaldehyde and heptane. Following two washes, embryos were stained with X-gal staining solution, permeabilized, and stained with primary antibody, and second antibody. Embryos labeled with fluorescent antibody were double-labeled with anti-b-galactosidase antibody to identify mutant embryos in situ hybridization was performed by the method of Tautz and Pfeiffle (1989) .
Stained embryos were examined under a Zeiss Axioscope microscope.
Flat preparation of embryos
Flat preparations (used for fluorescent staining in Fig. 1 ), were prepared essentially according to Bate (1990) ; live embryos were dechorionated and the vitteline membrane was removed by hand. The embryos were opened and flattened on poly-l-Lysine covered coverslips, fixed with 3% paraformaldehyde in PBS, and stained.
Western analysis
Embryos containing either UAS-vein or UAS-sspitz, in addition to hs-gal4 inducer and also hs-gal4/ + embryos, were collected for 2 h, incubated for 3 h at 25°C, heatshocked at 37°C for 20 min, and returned to 29°C for 3 h. Embryos were boiled in sample buffer and subjected to SDS-PAGE and Western analysis. HRP-conjugated-antibody was used and detected by Super signal substrate (Pierce). Each lane represents 15 embryos. The intensity of the bands was analyzed using NIH Image version 1.55 (NIH, MD, USA). The intensities of the MAPK reactive band and of a control band, were calculated for each cross, and the ratio between these numbers was compared to the corresponding ratio of the control experiment (hs-gal4/ + embryos).
Confocal microscopy
Fluorescent labeled preparations were imaged using a BioRad MRC 1024 confocal microscope coupled to a Zeiss Axiovert 135M microscope. Bright field and fluorescent digital images were processed using Photoshop version 3.0 (Adobe Systems Inc., CA, USA).
